Regulatory considerations in production of a cell therapy medicinal product in Europe to clinical research
- PMID: 23014774
- DOI: 10.1007/s10238-012-0213-6
Regulatory considerations in production of a cell therapy medicinal product in Europe to clinical research
Abstract
The development of new drugs using stem cells has become a clinic alternative for the treatment of different diseases such as Alzheimer's, diabetes and myocardial infarction. Similar to conventional medicines, stem cells as new medicinal products for cell therapy are subjected to current legislation concerning their manufacture process. Besides, their legality is determined by the Regulatory Agencies belonging to the Member State of the European Union in which they are being registered. With the evolution of therapy that uses cells as medicines, there is a need to develop the appropriate legislative and regulatory framework capable of ensuring their safety and effectiveness. However, few works have been published regarding the regulations that these products must comply through production and commercialization processes. The present work is focused on the description of key events during clinical development and cell production of stem cells as drugs. Such as the regulations, requirements and directives involved in the production of cell therapy medicinal products, from the clinical design stage to its commercialization in Europe.
Similar articles
-
[Regulatory requirements regarding cell-based medicinal products for human and veterinary use - a comparison].Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2015 Nov;58(11-12):1299-305. doi: 10.1007/s00103-015-2247-x. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2015. PMID: 26369765 Review. German.
-
Comparative analysis of regulations and studies on stem cell therapies: focusing on induced pluripotent stem cell (iPSC)-based treatments.Stem Cell Res Ther. 2024 Nov 21;15(1):447. doi: 10.1186/s13287-024-04065-9. Stem Cell Res Ther. 2024. PMID: 39574212 Free PMC article. Review.
-
Development of a cell-based medicinal product: regulatory structures in the European Union.Br Med Bull. 2013;105:85-105. doi: 10.1093/bmb/lds036. Epub 2012 Nov 25. Br Med Bull. 2013. PMID: 23184855 Review.
-
European regulation for therapeutic use of stem cells.Biomed Mater Eng. 2017;28(s1):S3-S7. doi: 10.3233/BME-171619. Biomed Mater Eng. 2017. PMID: 28372273
-
Marketing Regulatory Oversight of Advanced Therapy Medicinal Products (ATMPs) in Europe: The EMA/CAT Perspective.Adv Exp Med Biol. 2015;871:103-30. doi: 10.1007/978-3-319-18618-4_6. Adv Exp Med Biol. 2015. PMID: 26374215 Review.
Cited by
-
Standard requirement of a microbiological quality control program for the manufacture of human mesenchymal stem cells for clinical use.Stem Cells Dev. 2014 May 15;23(10):1074-83. doi: 10.1089/scd.2013.0625. Epub 2014 Feb 20. Stem Cells Dev. 2014. PMID: 24417334 Free PMC article.
-
Clinical research skills development program in cell-based regenerative medicine.Stem Cells Transl Med. 2015 Feb;4(2):118-22. doi: 10.5966/sctm.2014-0144. Epub 2014 Dec 29. Stem Cells Transl Med. 2015. PMID: 25548389 Free PMC article.
-
Stability enhancement of clinical grade multipotent mesenchymal stromal cell-based products.J Transl Med. 2018 Oct 24;16(1):291. doi: 10.1186/s12967-018-1659-4. J Transl Med. 2018. PMID: 30355298 Free PMC article.
-
Bone Regeneration with Mesenchymal Stem Cells in Scaffolds: Systematic Review of Human Clinical Trials.Stem Cell Rev Rep. 2024 May;20(4):938-966. doi: 10.1007/s12015-024-10696-5. Epub 2024 Feb 26. Stem Cell Rev Rep. 2024. PMID: 38407793 Free PMC article.
-
Principal Criteria for Evaluating the Quality, Safety and Efficacy of hMSC-Based Products in Clinical Practice: Current Approaches and Challenges.Pharmaceutics. 2019 Oct 24;11(11):552. doi: 10.3390/pharmaceutics11110552. Pharmaceutics. 2019. PMID: 31652984 Free PMC article. Review.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources